Clinical trials
Phase 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Amgen | 1 |
| Bristol-Myers Squibb | 1 |
| Charite University, Berlin, Germany | 1 |
| Children's Oncology Group | 1 |
| Gamida Cell ltd | 1 |
| Kiadis Pharma | 1 |
| Mats Heyman | 1 |
| Pfizer | 1 |
| Princess Maxima Center for Pediatric Oncology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 |
| Leukemia, Myeloid, Acute | 4 |
| Burkitt Lymphoma | 3 |
| Leukemia | 3 |
| Leukemia, Biphenotypic, Acute | 3 |
| Lymphoma | 3 |
| Myelodysplastic Syndromes | 3 |
| Hematologic Neoplasms | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Leukemia, Myeloid, Accelerated Phase | 2 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.